1379401
USP
美洛昔康
United States Pharmacopeia (USP) Reference Standard
别名:
4-羟基-2-甲基- N -（5-甲基-2-噻唑基）-2 H -1,2-苯并噻嗪-3-甲酰胺 1,1-二氧化物
等级
pharmaceutical primary standard
API类
meloxicam
制造商/商品名称
USP
应用
pharmaceutical (small molecule)
包装形式
neat
InChI
1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,19H,1-2H3,(H,15,16)/b13-11+
InChI key
DWMREKMVXIFPFM-ACCUITESSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
本产品按照发行药典的发行和规定提供。支持本产品的所有信息，包括安全数据表和任何产品信息传单，都是在发行药典的授权下开发和发布的。如需进一步信息和支持，请访问现行药典网站。
应用
美洛昔康USP参标准品，预期用途是USP规定的指定质量测试和检测。也用于USP各论，例如：
- 美洛昔康口服混悬液
- 美洛昔康片
分析说明
这些产品仅供测试和化验使用。它们不适用于人类或动物，也不能用于诊断、治疗或治愈任何类型的疾病。
其他说明
可能适用相应的销售限制。
警示用语：
Danger
危险声明
危险分类
Acute Tox. 3 Oral
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
[The new nonsteroidal anti-inflammatory preparation meloxicam in the treatment of rheumatoid arthritis].
E I Grishina
Likars'ka sprava, (2)(2), 19-25 (1997-03-01)
Mansoor Ahmed et al.
Expert opinion on drug metabolism & toxicology, 1(4), 739-751 (2006-07-26)
Rheumatoid arthritis (RA), a chronic inflammatory multisystem disorder marked by joint pain, stiffness, swelling and multiple systemic involvements, requires a multifaceted approach for its management. It includes symptomatic treatment with analgesics as well as disease-modifying medications to alter the course
S Noble et al.
Drugs, 51(3), 424-430 (1996-03-01)
Meloxicam is a new nonsteroidal anti-inflammatory drug (NSAID) developed for the treatment of rheumatoid arthritis and osteoarthritis. It has greater in vitro and in vivo inhibitory action against the inducible isoform of cyclo-oxygenase (COX-2), which is implicated in the inflammatory
Relative value of the NSAIDs, including COX-2 inhibitors and meloxicam.
Frederic R Curtiss
Journal of managed care pharmacy : JMCP, 12(3), 265-268 (2006-04-21)
D E Furst
Seminars in arthritis and rheumatism, 26(6 Suppl 1), 21-27 (1997-06-01)
Nonsteroidal antiinflammatory drugs (NSAIDs) exert their actions by inhibiting cyclooxygenase (COX). It has recently been postulated that NSAIDs' antiinflammatory efficacy arises from inhibition of the COX-2 isoform of cyclooxygenase, whereas inhibition of the COX-1 isoform produces the troublesome and sometimes
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持